الفهرس 
Aim of the studyOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
CRC is the third most commonly diagnosed cancer and the
fourth leading cause of cancer death worldwide. Globally, over 1.3
million new cases (9.7) were diagnosed and approximately 690,000
deaths (8.5 %) in 2014.
In Egypt, CRC is the 7th commonest cancer in Egypt
representing 3.4% of male cancers and 3% of female cancers.
CRC presents with different symptoms depending on the region
of origin in the colon and the stage at presentation. Initial symptoms
of CRC may include microcytic anemia due to occult blood loss,
fatigue, unintentional significant weight loss, abdominal colic, change
in bowel habits.
Surgery is the primary and curative treatment for CRC, and the
role of postoperative chemotherapy to improve disease-free and
overall survival for high-risk colorectal patients is well-established,
but is still not able to prevent recurrence in all patients. So there are
multiple ongoing researches for alternative compounds to be used as
adjuvant therapy.
One of these targets is HER2/neu, which is primarily associated
with breast cancer. So, the aim of this study is to evaluate of HER2/
neu expression in patients with colorectal cancer and Its Relation to
other clinicopathological variables and Prognostic Factors.
Overexpression of the HER2/neu gene is an independent
predictor of a shorter overall survival and time to relapse in patients
with breast cancer.
Several studies are done to evaluate HER2/neu in CRC which
resulted in a large debate because expression rates varied between
zero and 84%.
Various therapeutic approaches are being tested in HER2/neu
positive CRC patients (trastuzumab plus lapatinib),(trastuzumab plus
pertuzumab), achieving clinical benefit in 70% of patients and an
overall response rate of 30%.
HER2/neu evaluation is done according to scoring of breast and
gastric carcinoma. No other studies evaluate HER2/neu by the two
methods. HER2/neu expression according to scoring of breast cancer
was detected in 19 cases (31.6%) of patients with CRC. HER2/neu
expression according to scoring of gastric carcinoma was detected in
12 patients (22.6%) of patients with CRC.
There is no statistically difference between two methods as
regard relation between HER2/neu and different clinicopathological
features.
HER2/neu overexpression is associated with higher TNM
stages and positive nodal status. There is no statistically difference in
OS and PFS. But, HER2/neu-positive CRCs showed a tendency to
poorer survival. Although statistically in significant, Right-sided colon
cancer tends to be poorer prognosis than Left-sided colon cancer.